18 F‐PSMA‐1007 PET/CT Demonstrates Higher Accuracy for Biochemically Recurrent Prostate Cancer Compared to Contemporary Conventional Imaging
Advances in Urology · 2026-01 · 2026 (1)
DOI: 10.1155/aiu/8550174 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Urology, online erschienen am 05.07.2026. Verfasst von Zachary Stanton und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada, ualberta.ca. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alberta Cancer Foundation.
Abstract (Originalsprache)
Purpose
The goal of this study was to compare the accuracy of 18 F‐PSMA‐1007 PET/CT to contemporary conventional imaging (contrast‐enhanced CT scan of the chest, abdomen, and pelvis and a 99m Tc‐MDP whole body bone scan with SPECT/CT of the torso) in the setting of biochemically recurrent prostate cancer.
Methods
This prospective nonrandomized Phase II cohort study clinical trial included 85 patients with biochemically recurrent prostate cancer (previous therapy). 18 F‐PSMA‐1007 whole body PET/CT imaging was performed in all patients, with conventional imaging (contrast‐enhanced CT scan of the chest, abdomen, and pelvis and a 99m Tc‐MDP whole body bone scan with SPECT/CT of the torso) then performed within 12 days. PROMISE criteria were used for PET/CT interpretation. After a minimum 1‐year follow‐up period, lesion‐level and patient‐level analyses were performed based on previously published reference criteria (Lawhn‐Heath et al. 2019). The accuracy data were compared. Referring physicians were surveyed to help determine if the scans altered treatment. Categorical variables were compared using the McNemar test ( p < 0.05 significant).
Results
53 patients with a total of 72 evaluable lesions were included in the analysis. 18 F‐PSMA‐1007 PET/CT had a higher sensitivity than conventional imaging on a lesion level (100% compared with 58.3%) and higher overall accuracy on a patient level (90.6% compared with 62.3%, p < 0.05). The referring physicians felt that the 18 F‐PSMA‐1007 PET/CT scans were beneficial to the clinical care of the patient in 90.6% of cases.
Conclusion
Overall, the findings support the use of 18 F‐PSMA‐1007 over conventional imaging in the evaluation of patients with biochemically recurrent prostate cancer. Trial Registration: ClinicalTrials.gov.identifier: NCT04733768
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada, ualberta.ca.
- Department of Oncology, University of Alberta, Edmonton, Alberta, Canada, ualberta.ca.
- Department of Surgery, University of Alberta, Edmonton, Alberta, Canada, ualberta.ca.
ORCID-Profile: Ryan Hung, Jonathan Abele
Förderung
- Alberta Cancer Foundation
Zitieren
APA
Stanton, Z., Woloschuk, B., Tamm, A., Hung, R., Trivedi, A., Kolinsky, M., Usmani, N., Rowe, L., Moore, R., Wuest, F., & Abele, J. (2026). 18 F‐PSMA‐1007 PET/CT Demonstrates Higher Accuracy for Biochemically Recurrent Prostate Cancer Compared to Contemporary Conventional Imaging. Advances in Urology, 2026(1). https://doi.org/10.1155/aiu/8550174
Vancouver
Stanton Z, Woloschuk B, Tamm A, Hung R, Trivedi A, Kolinsky M, et al. 18 F‐PSMA‐1007 PET/CT Demonstrates Higher Accuracy for Biochemically Recurrent Prostate Cancer Compared to Contemporary Conventional Imaging. Advances in Urology. 2026;2026(1). doi:10.1155/aiu/8550174
BibTeX
@article{Stanton2026,
author = {Stanton, Zachary and Woloschuk, Bonnie and Tamm, Alexander and Hung, Ryan and Trivedi, Adwait and Kolinsky, Michael and Usmani, Nawaid and Rowe, Lindsay and Moore, Ronald and Wuest, Frank and Abele, Jonathan},
title = {18 F‐PSMA‐1007 PET/CT Demonstrates Higher Accuracy for Biochemically Recurrent Prostate Cancer Compared to Contemporary Conventional Imaging},
journal = {Advances in Urology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/aiu/8550174}
}
EUVIMED